EQS-News: BIO-Europe Set to Break Records in Munich, Germany 27.09.2023, 14:00 Uhr von EQS News Jetzt kommentieren: 0

EQS-News: EBD Group / Key word(s): Conference
BIO-Europe Set to Break Records in Munich, Germany

27.09.2023 / 14:00 CET/CEST
The issuer is solely responsible for the content of this announcement.


PRESS RELEASE

For Immediate Release

BIO-Europe Set to Break Records in Munich, Germany

MUNICH, GERMANY – September 27, 2023 – BIO-Europe, the premier partnering conference for the global biopharmaceutical industry, is gearing up for its 29th edition, which is set to be the largest and most internationally diverse event to date. With current registration patterns signalling remarkable growth and a substantial increase in global participation, BIO-Europe 2023 promises to be an unparalleled opportunity for collaboration and innovation in the biopharma sector.

Scheduled to take place from November 6–8, 2023, in the vibrant city of Munich, Germany, BIO-Europe has established itself as the epicenter of biopharmaceutical partnering, attracting leaders, innovators, and decision-makers from across the world. The event is proudly organized by EBD Group and hosted on partneringONE®, a state-of-the-art digital platform that facilitates meaningful connections and collaborations.

As the countdown to BIO-Europe 2023 begins, the organizers are thrilled with the ongoing enthusiasm and support from the global biopharma community. Current registration trends indicate a substantial surge in interest, with over 5,000 delegates anticipated to convene in Munich and participate in over 27,000 one-to-one meetings to drive life science global dealmaking to new levels. Additionally, the event will feature three days of program sessions; attendees will learn the important trends and opportunities in the life sciences from some of the brightest minds in the sector. The agenda has been built around three themes: the Business of Biotech, Therapeutic Insights, and Ecosystem Innovation.  

In addition to the main event, BIO-Europe is extending its reach further by hosting digital partnering days on November 14–15, 2023, which will be accessible through partneringONE®. These days will welcome an additional opportunity for participants to connect, collaborate, and explore potential partnerships.

"Each year, BIO-Europe raises the bar for what a biopharmaceutical partnering event can achieve. The overwhelming response from the global life sciences industry is a testament to the event's reputation as your 'gateway to the global biopharma community,’” said Claire Macht, European Portfolio Director for EBD Group. “We are thrilled to witness the continued growth and international appeal of BIO-Europe, and we look forward to welcoming over 5,000 delegates to Munich. Together, we will catalyse innovation, foster collaborations, and accelerate the biopharma industry forward."

partneringONE® is now open! Registered attendees are already busy scheduling their one-to-one meetings. Register today to secure your spot at BIO-Europe 2023 and unlock endless possibilities for collaboration and growth.

BIO-Europe is produced by EBD Group, the leading partnering firm for the global biotechnology industry, with the support of the Biotechnology Innovation Organization (BIO).  

For more information, please visit the conference website at: https://informaconnect.com/bioeurope  

Additional links and information: 

Follow BIO-Europe 2023 on X (formerly Twitter) @EBDGroup (hashtag: #BIOEurope) or on LinkedIn

About EBD Group 

EBD Group’s overriding mission is to help collaborations get started across the life science value chain. Our range of partnering conferences has grown to become the largest and most productive conference platform in the industry. Each one of our landmark events held in key life science markets around the world is powered by our state-of-the-art partnering software, partneringONE®, that enables delegates to efficiently identify and engage with new opportunities via one-to-one meetings. Today our events (BIO-Europe®, BIO-Europe Spring®, BioPharm America™, Biotech Showcase™, ChinaBio® Partnering Forum, and BioEquity Europe) annually attract more than 15,000 senior life science executives who engage in over 50,000 one-to-one partnering meetings. These vital one-to-one engagements are the wellspring of deals that drive innovation in our industry. EBD Group is an Informa company. For more information, please visit www.ebdgroup.com.

Media Contacts:
MC Services AG 
+49 89 2102280 
contact@mc-services.eu  

Karina Marocco
EBD Group
kmarocco@ebdgroup.com



27.09.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


1733889  27.09.2023 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1733889&application_name=news&site_id=boersennews
Kommentare (0) ... diskutiere mit.
Werbung

Handeln Sie Aktien bei SMARTBROKER+ für 0 Euro!* Profitieren Sie von kostenloser Depotführung, Zugriff auf 29 deutsche und internationale Börsenplätze und unschlagbar günstigen Konditionen – alles in einer innovativen, brandneuen App. Jetzt zu SMARTBROKER+ wechseln und durchstarten!

*Ab 500 EUR Ordervolumen über gettex. Zzgl. marktüblicher Spreads und Zuwendungen.

k.A. k.A. k.A. k.A.
k.A. k.A. k.A. k.A.
k.A. k.A. k.A. k.A.
Schreib den ersten Kommentar!

Dis­clai­mer: Die hier an­ge­bo­te­nen Bei­trä­ge die­nen aus­schließ­lich der In­for­ma­t­ion und stel­len kei­ne Kauf- bzw. Ver­kaufs­em­pfeh­lung­en dar. Sie sind we­der ex­pli­zit noch im­pli­zit als Zu­sich­er­ung ei­ner be­stim­mt­en Kurs­ent­wick­lung der ge­nan­nt­en Fi­nanz­in­stru­men­te oder als Handl­ungs­auf­for­der­ung zu ver­steh­en. Der Er­werb von Wert­pa­pier­en birgt Ri­si­ken, die zum To­tal­ver­lust des ein­ge­setz­ten Ka­pi­tals füh­ren kön­nen. Die In­for­ma­tion­en er­setz­en kei­ne, auf die in­di­vi­du­el­len Be­dür­fnis­se aus­ge­rich­te­te, fach­kun­di­ge An­la­ge­be­ra­tung. Ei­ne Haf­tung oder Ga­ran­tie für die Ak­tu­ali­tät, Rich­tig­keit, An­ge­mes­sen­heit und Vol­lständ­ig­keit der zur Ver­fü­gung ge­stel­lt­en In­for­ma­tion­en so­wie für Ver­mö­gens­schä­den wird we­der aus­drück­lich noch stil­lschwei­gend über­nom­men. Die Mar­kets In­side Me­dia GmbH hat auf die ver­öf­fent­lich­ten In­hal­te kei­ner­lei Ein­fluss und vor Ver­öf­fent­lich­ung der Bei­trä­ge kei­ne Ken­nt­nis über In­halt und Ge­gen­stand die­ser. Die Ver­öf­fent­lich­ung der na­ment­lich ge­kenn­zeich­net­en Bei­trä­ge er­folgt ei­gen­ver­ant­wort­lich durch Au­tor­en wie z.B. Gast­kom­men­ta­tor­en, Nach­richt­en­ag­en­tur­en, Un­ter­neh­men. In­fol­ge­des­sen kön­nen die In­hal­te der Bei­trä­ge auch nicht von An­la­ge­in­te­res­sen der Mar­kets In­side Me­dia GmbH und/oder sei­nen Mit­ar­bei­tern oder Or­ga­nen be­stim­mt sein. Die Gast­kom­men­ta­tor­en, Nach­rich­ten­ag­en­tur­en, Un­ter­neh­men ge­hör­en nicht der Re­dak­tion der Mar­kets In­side Me­dia GmbH an. Ihre Mei­nung­en spie­geln nicht not­wen­di­ger­wei­se die Mei­nung­en und Auf­fas­sung­en der Mar­kets In­side Me­dia GmbH und de­ren Mit­ar­bei­ter wie­der. Aus­führ­lich­er Dis­clai­mer